Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4467165 | 0.73 | CYP1A2 (0.39) | NOS1CA12CA9CYP2A6 | |
| SCHEMBL4461751 | 0.73 | ALDH1A1 (0.39) | CA9CYP2A6 | |
| SCHEMBL16289768 | 0.73 | CYP1A2 (0.39) | CA12 | |
| SCHEMBL16289590 | 0.68 | CA1 (0.40) | — | |
| SCHEMBL5543632 | 0.68 | CES1 (0.33) | — | |
| SCHEMBL2519617 | 0.68 | ALDH1A1 (0.48) | CYP2A6 | |
| SCHEMBL16289425 | 0.66 | — | — | |
| SCHEMBL456807 | 0.65 | BACE1 (0.33) | BACE1NOS1CA12CA9CYP2A6 | |
| SCHEMBL5544077 | 0.65 | SCN9A (0.36) | — | |
| SCHEMBL5537528 | 0.64 | AHR (0.34) | BACE1NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| CN-101255170-A | 2,3-dihydroimidazo[2,1-b]oxazole compound | OTSUKA PHARMA CO LTD (JP) | 2008-09-03 | — | — | CN | disclosed |
| CN-101172981-A | 2,3-dihydroimidazo[2,1-b]oxazole compound | OTSUKA PHARMA CO LTD (JP) | 2008-05-07 | — | — | CN | disclosed |
| CN-100366624-C | 2, 3-dihydro-6-nitroimidazo [2,1-b ] * azole compounds | OTSUKA PHARMA CO LTD (JP) | 2008-02-06 | — | — | CN | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| CN-1705670-A | 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds | OTSUKA PHARMA CO LTD (JP) | 2005-12-07 | — | — | CN | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| CN-1204126-C | Process for preparing pyridazin-2-one derivs. | SUMITOMO CHEMICAL CO (JP) | 2005-06-01 | — | — | CN | disclosed |
| EP-1137641-B1 | PROCESS FOR PREPARING PYRIDAZIN-3-ON DERIVATIVES | SUMITOMO CHEMICAL CO (JP) | 2004-11-10 | — | — | EP | disclosed |
| US-6500951-B1 | RING CLOSING A CARBOXYLIC ACID DERIVATIVE IN PRESENCE OF A NITROGEN CONTAINING AROMATIC COMPOUND AND A BORON COMPOUND; HIGH YIELD AND PURITY | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-12-31 | — | — | US | disclosed |
| CN-1334805-A | Process for preparing pyridazin-2-one derivs. | SUMITOMO CHEMICAL CO (JP) | 2002-02-06 | — | — | CN | disclosed |
| EP-1137641-A1 | PROCESS FOR PREPARING PYRIDAZIN-3-ON DERIVATIVES | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2001-10-04 | — | — | EP | disclosed |
| WO-2000034249-A1 | PROCESS FOR PREPARING PYRIDAZIN-3-ON DERIVATIVES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2000-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | BACE1 3399/4885NOS1 553/4885CA12 1998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.